Acute pain in oncology: specific features and treatment options. What is new?

Background: Cancer patients experience acute pain at various the stages of antitumor therapy, which can reduce the patient's commitment to treatment and trust in the doctor, therefore, rapid relief of acute pain is very important. Objective: The aims of the article is to describe the options for acute pain relief in oncology, to characterize the main groups of analgetics, to present data of clinical trials and clinical cases of the use of Tafalgin — the new generation drug from the group of central analgesics.

Methods: Analysis of the literature on pain therapy in cancer therapy, and own data within the framework of the multicenter study “Observational program for monitoring the effectiveness and safety of Tafalgin® in real clinical practice — NIKITA”.

Results: The classification of acute pain in cancer patients in cancer therapy is proposed, analgesics and the features of their use depending on the intensity of pain are described. The results of Tafalgin use show that in 15 minutes after its subcutaneous administration there was a decrease in the intensity of pain by 59.6 %. The duration of analgesia reached 9.35 ± 6.3 hours. An acceptable level of pain relief was achieved in 84 % of patients. 19 mild and moderate adverse events were detected in 15 patients.

Conclusion: Acute pain in cancer patients continues to be a problem, despite the large number of analgesics, so the introduction into clinical practice of a new effective analgesic Tafalgin might ensure pain control.

1. van den Beuken-van Everdingen M.H., Hochstenbach L.M., Joosten E.A., et al. Update on prevalence of pain in patients with cancer: systematic review and meta-analysis. J Pain Symptom Manage 2016;51(6):1070-90. https://doi.Org/10.1016/j.jpainsymman.2015.12.340

2. Snijders R.A.H., Brom L., Theunissen M., van den Beuken-van Everdingen M.H.J. Update on Prevalence of Pain in Patients with Cancer 2022: A Systematic Literature Review and Meta-Analysis. Cancers (Basel) 2023;15(3):591. https://doi.org/10.3390/cancersl5030591

3. Clinical Guidelines “Chronic pain syndrome in adult patients in need of palliative care” (revised in 2023) (In Russ.). Available at: https://cr.minzdrav.gov.ru/recomend/400_2

4. Recommendations on RUSSCO supportive and accompanying therapy (revised in 2022, with amendments in 2023) (In Russ.). Available at: https://rosoncoweb.ru/standarts/suptherapy/ (In Russ.)

5. Delgado-Guay M.O., Kim Y.J., Shin S.H., et al. Avoidable and unavoidable visits to the emergency department among patients with advanced cancer receiving outpatient palliative care. J Pain Symptom Manage 2015;49(3):497-504. https://doi.org/10.1016/j.jpainsymman.2014.07.00

6. Patnaik S., Turner J., Inaparthy P., Kieffer W.K. Metastatic spinal cord compression. Br J Hosp Med (Lond) 2020;81(4):l-10. https://doi.org/10.12968/hmed.2019.0399

7. Pituskin E., Fairchild A., Dutka J., et al. Multidisciplinary team contributions within a dedicated outpatient palliative radiotherapy clinic: a prospective descriptive study. Int J Radiat Oncol Biol Phys 2017;78(2):527-32. https://doi.org/10.1016/j.ijrobp.2009.07.1698

8. Lachgar A., Toulba A., Kebdani T., et al. Radiotherapy in the management of painful bone metastases at The National Institute of Oncology in Morocco: data from one year follow-up of 86 patients. Tunis Med 2015;93(8-9):574-577

9. Kirou-Mauro A.M., Hird A., Wong J., et al. Has pain management in cancer patients with bone metastases improved? A seven-year review at an outpatient palliative radiotherapy clinic. J Pain Symptom Manage 2009;37(l):77-84. https://doi.org/https//doi.org/10.1016/j.jpainsymman.2007.12.014

10. Hird A., Chow E., Zhang L., et al. Determining the incidence of pain flare following palliative radiotherapy for symptomatic bone metastases: results from three Canadian cancer centers. Int J Radiat Oncol Biol Phys 2009;75(l):193-7. https://doi.Org/10.1016/j.ijrobp.2008.10.044

11. Fallon M., Giusti R., Aielli F., et al. Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines. Ann Oncol 2018;29(Suppl. 4):ivl66-ivl91. https//doi.org/10.1093/annonc/mdyl52

12. Logan R.M., Al-Azri A.R., Bossi Р., et al. Systematic review of growth factors and cytokines for the management of oral mucositis in cancer patients and clinical practice guidelines. Support Care Cancer 2020;28(5):2485-2498. https//doi.org/10.1007/s00520-019-05170-9

13. Elad S. The MASCC/ISOO mucositis guidelines 2019: The second set of articles and future directions. Support Care Cancer 2020;28(5):2445-2447. https//doi.org/10.1007/s00520-019-05153-w

14. Sobue T., Bertolini M., Thompson A., et al. Chemotherapy-induced oral mucositis and associated infections in a novel organotypic model. Mol Oral Microbiol 2018;33(3):212-223. https//doi.org/10.1111/omi.12214

15. Sroussi H.Y., Epstein J.B., Bensadoun R.J., et al. Common oral complications of head and neck cancer radiation therapy: Mucositis, infections, saliva change, fibrosis, sensory dysfunctions, dental caries, periodontal disease, and osteoradionecrosis. Cancer Med 2017;6(12):2918-2931. https//doi.org/10.1002/cam4.1221

16. Pulito C., Cristaudo A., La Porta C., et al. Oral mucositis: the hidden side of cancer therapy. J Exp Clin Cancer Res 2020;39(l):210. https//doi.org/10.1186/sl3046-020-01715-7

17. Anesteziologiya і intensivnaya terapiya v onkologii/V.E. Horonenko; pod red. akademika RAN, professora A.D. Kaprina M.: Molodaya gvardiya, 2021376 s (In Russ.)

18. Ovechkin А.М., Bayalieva A.Zh., Ezhevskaya A.A. і dr. Posleoperacionnoe obezbolivanie. Klinicheskie rekomendacii. Vestnik intensivnoj terapii im. A.I. Saltanova. 2019;4:9-33 (In Russ.)

19. Gruzdev V.E., Anisimov М.А., Ryabuhina Yu.E., et al. New peptide analgesic, pl-opioid receptor agonist tafalgin, in multimodal pain management. First results of using in a multidisciplinary hospital. MD-Onco. 2024;4(l):78-84 (In Russ.), https://doi.org/10.17650/2782-3202-2024-4-l-78-84

20. Cata J.P., Corrales G., Speer B, Owusu-Agyemang P. Postoperative acute pain challenges in patients with cancer. Best Pract Res Clin Anaesthesiol 2019;33(3):361—371. https://doi.Org/10.1016/j.bpa.2019.07.018

21. Fairbairn L., Schuberth A., Deacon L., et al. A systematic review of subcutaneous versus intramuscular or intravenous routes of opioid administration on pain outcomes in cancer and post-surgical clinical populations challenging current assumptions in palliative care practice. BrJ Pain 2023;17(2):152—165. https://doi.org/10.1177/20494637221135835

22. Lekarstvennye sredstva. Mashkovskij M.D.M.: NovayaVolna; 2021.1216 p. (In Russ.)

23. Leiva-Vasquez O., Letelier L.M., Rojas L., et al. Is Acetaminophen beneficial in patients with cancer pain who are on strong opioids? A randomized controlled trial. J Pain Symptom Manage 2023;66(3):183-192.el. https://doi.org/10.1016/j.jpainsymman.2023.05.002

24. Wiffen P.J., Derry S., Moore R.A., et al. Oral paracetamol (acetaminophen) for cancer pain. Cochrane Database Syst Rev2017;7(7):CD012637. https://doi.org/10.1002/14651858.CD012637

25. Bindu S., Mazumder S., Bandyopadhyay U. Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspective. Biochem Pharmacol 2020;180:114147. https://doi.Org/10.1016/j.bcp.2020.114147

26. Fine P.G. Treatment guidelines for the pharmacological management of pain in older persons. Pain Med 2012;13 Suppl 2:S57-66. https://doi.Org/10.llll/j.1526-4637.2011.01307.x

27. Wood H., Dickman A., Star A., Boland J.W. Updates in palliative care overview and recent advancements in the pharmacological management of cancer pain. Clin Med (Lond) 2018;18(l):17-22. https://doi.org/10.7861/clinmedicine.18-l-17

28. Hakkarainen T.W., Steele S.R., Bastaworous A., et al. Nonsteroidal anti-inflammatory drugs and the risk for anastomotic failure: a report from Washington State’s Surgical Care and Outcomes Assessment Program (SCOAP). JAMA Surg 2015;150(3):223-8. https://doi.org/10.1001/jamasurg.2014.2239

29. Pasutharnchat K., Wichachai W., Buachai R. Analgesic efficacy of nefopam for cancer pain: a randomized controlled study. FlOOORes 2020;9:378. https://doi.Org/10.12688/fl000research.23455.l

30. Girard P., Chauvin M., Verleye M. Nefopam analgesia and its role in multimodal analgesia: a review of preclinical and clinical studies. Clin Exp Pharmacol Physiol 2016;43(l):3-12. https://doi.org/10.llll/1440-1681.12506

31. Khoronenko VE, Petrova VV, Stenina II. Centrally-acting nonopioid analgesic nefopam in combination analgesia after cancer surgery. P.A. Herzenjournal of Oncology 2014;3(3):18 21 (In Russ.)

32. Na H.S., Oh A.Y., Koo B.W., et al. Preventive analgesic efficacy of nefopam in acute and chronic pain after breast cancer surgery: a prospective, double-blind, and randomized trial. Medicine (Baltimore) 2016;95(20):e3705. https://doi.org/10.1097/MD.0000000000003705

33. Yeo H., Choi J.W., Lee S., et al. The lack of analgesic efficacy of nefopam after video-assisted thoracoscopic surgery for lung cancer: a randomized, single-blinded, controlled trial. J Clin Med. 2022;ll(16):4849. https://doi.org/10.3390/jcmlll64849

34. Instructions for Nefopam medical use. The State Register of Medicinal Remedies of the Ministry of Health of the Russian Federation. Available at: https://grls.minzdrav.gov.ru/Grls_View_v2.aspx?routingGuid=59elc408-613a-4cd8adl3-8edc7890c872 (accessed 21.11.2024) (In Russ.)

35. Grond S., Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet 2004;43(13):879-923. https://doi.org/10.2165/00003088-200443130-00004

36. Instructions for Tramadol medical use. The State Register of Medicinal Remedies of the Ministry of Health of the Russian Federation. Available at: https://grls.minzdrav.gov.ru/Grls_View_v2.aspx?routingGuid=9falfb4f-838a-4570bel5-a9df759f5d51 (accessed 21.11.2024) (In Russ.)

37. Wade W.E., Spruill W.J. Tapentadol hydrochloride: a centrally acting oral analgesic. Clin Ther 2009;31(12):2804-18. https://doi.Org/10.1016/j.clinthera.2009.12.003

38. Hartrick C.T., Rodriguez Hernandez J.R. Tapentadol for pain: a treatment evaluation. Expert Opin Pharmacother 2012;13(2):283-6.https://doi.org/10.1517/14656566.2012.648616

39. Arbuck D.M., Abuzarova G.R., Alekseeva G.S. Opioids in pain syndrome management (part 1). Anesthesiology and resuscitation 2017;14(3):58-67 (In Russ.), https://doi.org/10.21292/2078-5658-2017-14-3-58-67

40. Instructions for Morphin medical use. The State Register of Medicinal Remedies of the Ministry of Health of the Russian Federation. Available at: https://grls.minzdrav.gov.ru/Grls_View_v2.aspx?routingGuid=73ed4el6-feff-40749c90-ee6809c48347 (accessed 21.11.2024) (In Russ.)

41. Instructions for Omnopon medical use. The State Register of Medicinal Remedies of the Ministry of Health of the Russian Federation. Available at: https://grls.minzdrav.gov.ru/Grls_View_v2.aspx?routingGuid=c9a6a7fa-c24f-4cee9e95-b4d81630c03a (accessed 21.11.2024) (In Russ.)

42. Instructions for Promedoli medical use. The State Register of Medicinal Remedies of the Ministry of Health of the Russian Federation. Available at: https://grls.minzdrav.gov.ru/Grls_View_v2.aspx?routingGuid=6a7b6f83-d75b-428b9c9f-327637516c5b (accessed 21.11.2024) (In Russ.)

43. Instructions for Nalbufini medical use. The State Register of Medicinal Remedies of the Ministry of Health of the Russian Federation. Available at: https://grls.minzdrav.gov.ru/Grls_View_v2.aspx?routingGuid=ae6112dd-a81e-451aa4ce-cle891f7ed61 (accessed 21.11.2024) (In Russ.)

44. Instructions for Morphini hydrochloride in tab. medical use. The State Register of Medicinal Remedies of the Ministry of Health of the Russian Federation. Available at: https://grls.minzdrav.gov.ru/Grls_View_v2.aspx?routingGuid=0843a50e-2288-4786-81e4-clff019d759a (accessed 21.11.2024) (In Russ.)

45. Instructions for Morphini sol. for peroral.use. The State Register of Medicinal Remedies of the Ministry of Health of the Russian Federation. Available at: https://grls.minzdrav.gov.ru/Grls_View_v2.aspx?routingGuid=dc3fb5el-341c462b-a8f0-349977ee545b (accessed 21.11.2024) (In Russ.)

46. Instructions for Prosidoli. The State Register of Medicinal Remedies of the Ministry of Health of the Russian Federation. Available at: https://grls.minzdrav.gov.ru/Grls_View_v2.aspx?routingGuid=lde96aac-le41-4904-aa4b-2305c642e73a (accessed 21.11.2024) (In Russ.)

47. Instructions for Bupraxoni. The State Register of Medicinal Remedies of the Ministry of Health of the Russian Federation. Available at: https://grls.minzdrav.gov.ru/Grls_View_v2.aspx?routingGuid=lbdccld6-6798-4d56-b99a-f71673530405 (accessed 21.11.2024) (In Russ.)

48. Kosorukov V.S., Abuzarova G.R., Zaharochkina E.R., et al. Tafalgin is a Russian innovative tetrapeptide pharmaceutical for subcutaneous injection: review of the results of phase I and II clinical trials. Head and Neck Tumors 2022;12(2):89-107 (In Russ.), https://doi.org/10.17650/2222-1468-2022-12-2-89-107

49. Abuzarova G.R., Kosorukov V.S., Gamzeleva O.Yu., et al. The efficacy and safety of Tafalgin in patients with cancer pain. Results of an open-label comparative multicenter randomized clinical trial. P.A. Herzen Journal of Oncology. 2022;ll(5):38-48 (In Russ.), https://doi.org/10.17116/onkolog20221105138.